Elenbecestat
- Generic Name
- Elenbecestat
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18F3N5O2S
- CAS Number
- 1388651-30-6
- Unique Ingredient Identifier
- RXJ96XL94H
- Background
Elenbecestat is under investigation in clinical trial NCT02956486 (A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease).
Study to Evaluate the Safety and Tolerability of a Once Daily Dose of 50 mg E2609 in Healthy Japanese Subjects
- First Posted Date
- 2017-02-16
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT03055962
- Locations
- π―π΅
Eisai Trial Site, Fukuoka, Japan
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease
- First Posted Date
- 2016-11-06
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 2212
- Registration Number
- NCT02956486
- Locations
- π―π΅
Eisai Trial Site 1, Osaka, Japan
π¬π§Facility #1, London, United Kingdom
πΊπΈFacility #11, Miami, Florida, United States
A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects
- First Posted Date
- 2016-08-08
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02859207
Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease
Phase 2
Terminated
- Conditions
- Alzheimer DiseaseDementia, Alzheimer Type
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-12-22
- Last Posted Date
- 2021-03-05
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT02322021
A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects
- First Posted Date
- 2014-08-21
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT02222324
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects
- First Posted Date
- 2014-08-04
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02207790
A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2014-02-05
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 195
- Registration Number
- NCT02055703
- Locations
- πΊπΈ
WCT Early Development, San Antonio, Texas, United States
An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male Subjects
- First Posted Date
- 2013-11-05
- Last Posted Date
- 2016-01-08
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 113
- Registration Number
- NCT01975636
- Locations
- πΊπΈ
Covance Clinical Research Unit Inc., Madison, Wisconsin, United States
πΊπΈCovance Laboratories, Madison, Wisconsin, United States
An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2013-05-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT01716897
- Locations
- πΊπΈ
California Clinical Trials/Parexel, Glendale, California, United States
Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)
- First Posted Date
- 2012-05-17
- Last Posted Date
- 2016-12-30
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT01600859
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath